Newron Pharmaceuticals S.p.A. | WebDisclosure

Basculer en Français

10387	Companies
216934	Keywords
146632	Articles
114869	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

PRESS RELEASE

published on 02/03/2026 at 07:00, 3 months 9 days ago

Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia
Newron Pharmaceuticals S.p.A. announces publication highlighting Evenamide as adjunctive treatment in schizophrenia. Scientific evidence supports unique approach

Schizophrenia Publication Newron Pharmaceuticals Evenamide Adjunctive Treatment
BRIEF

published on 01/07/2026 at 07:05, 4 months 5 days ago

Début d'un essai clinique pour l'événamide au Japon

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Essai De Phase III EA Pharma
BRIEF

published on 01/07/2026 at 07:05, 4 months 5 days ago

Clinical Trial for Evenamide in Japan Commences

Phase III Trial Newron Pharmaceuticals Evenamide Schizophrenia Treatment EA Pharma
PRESS RELEASE

published on 01/07/2026 at 07:00, 4 months 5 days ago

Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan
Newron Pharmaceuticals S.p.A. announces Phase III Clinical Trial initiation with Evenamide, a novel Schizophrenia treatment in Japan, led by EA Pharma, a subsidiary of Eisai

Schizophrenia Newron Pharmaceuticals Evenamide Phase III EA Pharma
BRIEF

published on 01/06/2026 at 07:05, 4 months 6 days ago

Newron Pharmaceuticals Strengthens IP Portfolio for Evenamide

Patent Schizophrenia Newron Pharmaceuticals Evenamide Glutamate Modulation
BRIEF

published on 01/06/2026 at 07:05, 4 months 6 days ago

Newron Pharmaceuticals renforce son portefeuille de propriété intellectuelle pour Evenamide

Schizophrénie Brevet Newron Pharmaceuticals Evenamide Modulation Du Glutamate
PRESS RELEASE

published on 01/06/2026 at 07:00, 4 months 6 days ago

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Newron Pharmaceuticals obtains new EU Composition of Matter Patent EP4615820 for Evenamide, extending exclusivity into 2044

Patent Intellectual Property Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 12/08/2025 at 07:05, 5 months 4 days ago

Newron lance une étude de phase III aux États-Unis sur l'événamide pour la schizophrénie

Schizophrénie Essai Clinique Newron Pharmaceuticals Evenamide Étude De Phase III
BRIEF

published on 12/08/2025 at 07:05, 5 months 4 days ago

Newron Launches US Phase III Study on Evenamide for Schizophrenia

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide Phase III Study
PRESS RELEASE

published on 12/08/2025 at 07:00, 5 months 4 days ago

Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates ENIGMA-TRS 2 Phase III global clinical study in US for treatment-resistant schizophrenia with evenamide as add-on therapy. Expecting results by Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS 2

Accesswire

Published on 05/13/2026 at 00:00, 3 hours 35 minutes ago

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 4 hours ago

Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 5 hours 40 minutes ago

UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/12/2026 at 21:42, 5 hours 53 minutes ago

Kidoz Inc. to Present at Planet MicroCap Las Vegas 2026
Published on 05/12/2026 at 14:30, 13 hours 5 minutes ago

Pathfinder Ventures Inc. Announces Conclusion of Financing and Intention to Launch New Private Placement

View all ACCESSWIRE

EQS Group

Published on 05/12/2026 at 23:47, 3 hours 47 minutes ago

Nebius welcomes Clarifai’s core team and licenses inference IP to strengthen Nebius Token Factory
Published on 05/12/2026 at 22:25, 5 hours 9 minutes ago

Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Published on 05/12/2026 at 20:21, 7 hours 13 minutes ago

Nebius breaks ground on gigawatt-scale AI factory in Independence, Missouri
Published on 05/12/2026 at 19:35, 8 hours ago

AUSTRIACARD HOLDINGS AG: Q1 2026 Financial Results
Published on 05/12/2026 at 19:35, 8 hours ago

2026 Annual General Meeting: Strong vote by shareholders in favour of continuity in leadership and strategy

Les Echos

Published on 05/12/2026 at 18:15, 9 hours 20 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 30/04/2026
Published on 05/12/2026 at 18:15, 9 hours 20 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 30/04/2026
Published on 05/12/2026 at 18:10, 9 hours 25 minutes ago

imerys-12-05-2026-communiqué-compte-rendu-de-l-assemblée-générale-ordinaire-du-12-mai-2026
Published on 05/12/2026 at 18:10, 9 hours 25 minutes ago

imerys-12-05-2026-press-release-summary-of-the-ordinary-shareholders-general-meeting-12-may-2026
Published on 05/12/2026 at 17:50, 9 hours 45 minutes ago

Damartex fait évoluer sa gouvernance et engage une réflexion stratégique autour de ses activités

View all LES ECHOS COMFI WIRE